Polyphor presents AMR breaker
Swiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action of a new class of antibiotics.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1206 entries already.
Entries by Thomas Gabrielczyk
Zealand Pharma acquires Encycle
/in News/by Thomas GabrielczykZealand Pharma A/S has acquired Encycle Therapeutics Inc, including a peptide therapeutics platform and library.
Researchers target ferroptosis resistance of cancer cells
/in News/by Thomas GabrielczykGerman researchers have found a novel way to induce iron-induced necrosis, a process which they want to turn against cancer.
CHMP selects drugs for EU market approval
/in News/by Thomas GabrielczykEMAs human medicines committee (CHMP) recommended seven medicines for approval at its October 2019 meeting.
New risk factor for autism and epilepsy identified
/in News/by Thomas GabrielczykA molecular transporter is critical for the proper maturation of neurons underlying neurodevelopmental disorders.
Healx Ltd raises $56m in Series B financing
/in News/by Thomas GabrielczykAI-driven drug repurposing company Healx Ltd (Cambridge, UK) raises $56m in a Series B financing and launches global accelerator programme for orphan diseases.
4SC expands domatinostat combo testing
/in News/by Thomas GabrielczykThe Netherlands Cancer Institute (NKI) has joined 4SC AG as a partner in conducting a multicentre study of dominatostat/checkpoint blocker combos in treatment-native melanoma patients.
Cell transdifferentiation specialist Mogrify Ltd raises US$16m
/in News/by Thomas GabrielczykBritish start-up company Mogrify Ltd (Cambridge, UK) has added US$16m from a Series A round to its US$3.7m seed financing in February 2019. Existing investor Ahren Innovation Capital led the […]
Patient’s organoids predict response to chemotherapy
/in News/by Thomas GabrielczykA new test based on tumour organoids can predict how patients with advanced colorectal cancer (CRC) respond to chemotherapy treatment.
ADC Therapeutics enters licence option deal with Avacta Group
/in News/by Thomas GabrielczykADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer-drug conjugates.